Cornerstone Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: December 1, 2016
Pages: 50
Price:
US$ 499.00
Cornerstone Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: C7EF7C1886ABEN
Leaflet:

Download PDF Leaflet

Cornerstone Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Cornerstone Therapeutics Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Cornerstone Therapeutics Inc. and its competitors. This provides our Clients with a clear understanding of Cornerstone Therapeutics Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Cornerstone Therapeutics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Cornerstone Therapeutics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Cornerstone Therapeutics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Cornerstone Therapeutics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Cornerstone Therapeutics Inc. business.

About Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing products primarily for the respiratory and related markets.

Products

CUROSURF is an Food and Drug Administration (FDA)-approved natural lung surfactant for the treatment of Respiratory Distress Syndrome, or RDS, in premature infants.

FACTIVE is a fluoroquinolone with an activity against certain microorganisms implicated in certain respiratory infections, including multi-drug resistant strains of Streptococcus pneumoniae.

SPECTRACEF (cefditoren pivoxil) tablets are a third-generation cephalosporin indicated for the treatment of certain respiratory and skin infections.

ZYFLO CR is the only FDA-approved leukotriene synthesis inhibitor indicated for prophylaxis and chronic treatment of asthma.

The company’s other products, of which the most significant are ALLERX (combinations of methscopolamine nitrate, pseudoephedrine hydrochloride, phenylephrine hydrochloride and chlorpheniramine maleate) tablets and HYOMAX (hyoscyamine sulfate) tablets. Its ALLERX Dose Pack products consist of various oral tablet dose packs prescribed for the treatment of symptoms of allergic rhinitis.

The company’s HYOMAX family of products includes five antispasmodic medications containing an anticholinergic, which may be prescribed for functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis and irritable bowel syndrome, or IBS.

The company has also built a pipeline of products that includes line extensions for ZYFLO CR and SPECTRACEF, as well as a portfolio of additional product candidates that the company develops using controlled-release liquid technology licensed from Neos Therapeutics, L.P., or Neos.

Agreements

Jagotec — Manufacture and Supply Agreement for ZYFLO CR: Jagotec AG or Jagotec, a subsidiary of SkyePharma PLC, manufactures all of the company’s bulk, uncoated tablets of ZYFLO CR pursuant to a manufacture and supply agreement.

Patheon Pharmaceuticals Inc (Patheon)— Manufacturing Services Agreement for ZYFLO CR: Patheon coats, conducts quality control and quality assurance and stability testing and packages commercial supplies of ZYFLO CR for the company using uncoated ZYFLO CR tablets that the company supplies to Patheon.

Patheon— Commercial Manufacturing Agreement for ZYFLO Immediate-Release Tablets: Patheon also manufactures all of the company’s ZYFLO immediate-release tablets pursuant to a commercial manufacturing agreement. The company has agreed to purchase from Patheon approximately 50% of commercial supplies of ZYFLO immediate-release tablets for sale in the United States.

License and Collaboration Agreements

Chiesi Farmaceutici S.p.A. (Chiesi) — CUROSURF License and Distribution Agreement: In May 2009, the company entered into a series of agreements with Chiesi pursuant to which the company obtained a 10-year license to the U.S. commercial rights to Chiesi’s CUROSURF product and a two-year right of first offer on all drugs Chiesi intends to market in the United States.

LG Life Sciences — FACTIVE License and Option Agreement: In September 2009, the company acquired the commercial rights to the antibiotic FACTIVE (gemifloxacin mesylate) in North America and certain countries in Europe, certain inventory and related assets and specific product-related liabilities through the Oscient Agreement.

Meiji Seika Kaisha, Ltd. (Meiji) — SPECTRACEF License and Supply Agreement: In 2006, the company entered into a license and supply agreement with Meiji that grants the company a non-assignable U.S. license to manufacture and sell SPECTRACEF, using cefditoren pivoxil supplied by Meiji, for the company’s approved therapeutic indications and to use Meiji’s SPECTRACEF trademark in connection with the sale and promotion of SPECTRACEF for approved therapeutic indications.

Abbott Laboratories (Abbott) — Zileuton License Agreements: In 2003, the company acquired a worldwide license, under patent rights and know-how controlled by Abbott, to develop, make, use, and sell controlled-release and injectable formulations of zileuton for all c


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. CORNERSTONE THERAPEUTICS INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. CORNERSTONE THERAPEUTICS INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. CORNERSTONE THERAPEUTICS INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. CORNERSTONE THERAPEUTICS INC. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. CORNERSTONE THERAPEUTICS INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Cornerstone Therapeutics Inc. Direct Competitors
5.2. Comparison of Cornerstone Therapeutics Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Cornerstone Therapeutics Inc. and Direct Competitors Stock Charts
5.4. Cornerstone Therapeutics Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Cornerstone Therapeutics Inc. Industry Position Analysis

6. CORNERSTONE THERAPEUTICS INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. CORNERSTONE THERAPEUTICS INC. EXPERTS REVIEW1

7.1. Experts Opinion
7.2. Experts Estimates

8. CORNERSTONE THERAPEUTICS INC. ENHANCED SWOT ANALYSIS2

9. UNITED STATES PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. CORNERSTONE THERAPEUTICS INC. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. CORNERSTONE THERAPEUTICS INC. PORTER FIVE FORCES ANALYSIS2

12. CORNERSTONE THERAPEUTICS INC. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF TABLES

Cornerstone Therapeutics Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Cornerstone Therapeutics Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Cornerstone Therapeutics Inc. Major Shareholders
Cornerstone Therapeutics Inc. History
Cornerstone Therapeutics Inc. Products
Revenues by Segment
Revenues by Region
Cornerstone Therapeutics Inc. Offices and Representations
Cornerstone Therapeutics Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Cornerstone Therapeutics Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Cornerstone Therapeutics Inc. Capital Market Snapshot
Cornerstone Therapeutics Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Cornerstone Therapeutics Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Cornerstone Therapeutics Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

LIST OF FIGURES

Cornerstone Therapeutics Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Cornerstone Therapeutics Inc. 1-year Stock Charts
Cornerstone Therapeutics Inc. 5-year Stock Charts
Cornerstone Therapeutics Inc. vs. Main Indexes 1-year Stock Chart
Cornerstone Therapeutics Inc. vs. Direct Competitors 1-year Stock Charts
Cornerstone Therapeutics Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top


Ask Your Question

Cornerstone Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: